GSK plc (GSK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $101.13B
Last updated: Nov 17, 2026 at 4:25 PM ET
GSK plc (GSK) Statistics
GSK has a market cap of $101.13B. Its trailing P/E is 10.3x.
Total Valuation
| Market Cap | $101.13B |
|---|---|
| Latest price (Nov 17, 2026) | $49.23 |
Key Dates
The last ex-dividend date was Nov 13, 2026.
| Last Earnings Date | Oct 28, 2026 |
|---|---|
| Last Ex-Dividend Date | Nov 13, 2026 |
| Next Payment Date | Jan 7, 2027 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.3x and 4.0x.
| P/E Ratio | 10.3x |
|---|---|
| P/S Ratio | 2.3x |
| P/B Ratio | 4.0x |
| P/FCF Ratio | 11.1x |
| PEG Ratio | 2.2 |
Price Statistics
The stock is up 5.19% over 52 weeks and trades 0.65% above its 50-day average.
| Beta (1Y) | 0.28 |
|---|---|
| 52-Week Change | +5.19% |
| 1-Month Change | +0.42% |
| 3-Month Change | -6.08% |
| 6-Month Change | -2.70% |
| 5-Year Change | -6.43% |
| 10-Year Change | -1.00% |
| Total Return (1Y) | +9.14% |
| Total Return (3Y CAGR) | +14.53% |
| Total Return (5Y CAGR) | +2.08% |
| Return vs SPY (1Y) | -6.80% |
| Max Drawdown (1Y) | -23.82% |
| Max Drawdown (3Y) | -28.45% |
| Sharpe Ratio (1Y) | 0.18 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $48.91 |
| 200-Day Average | $51.72 |
| 52-Week Range | $44.23 to $59.57 |
| RSI (14 Days) | 48.0 |
| Average Volume (20 Days) | 3.77M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.86x current liabilities.
| Current Ratio | 0.86x |
|---|---|
| Quick Ratio | 0.56x |
| Interest Coverage | 8.80x |
Returns and Efficiency
Return on equity is 23.00% over the last 12 months, against a 5-year average of 50.66%.
| Return on Equity (ROE) | 23.00% |
|---|---|
| Return on Assets (ROA) | 6.02% |
| Return on Capital Employed (ROCE) | 12.70% |
| ROE (5Y Average) | 50.66% |
| ROA (5Y Average) | 10.20% |
| ROIC (5Y Average) | 14.52% |
| Asset Turnover | 0.43x |
| Inventory Turnover | 1.44x |
| Receivables Turnover | 4.04x |
| Cash Conversion Cycle | -259 days |
Taxes
Income tax took 10.42% of pretax income over the last 12 months.
| Income Tax (TTM) | GBP 559.17M |
|---|---|
| Effective Tax Rate | 10.42% |
Scores
GSK has an Altman Z-Score of 1.80, in the distress zone below 1.81, and a Piotroski F-Score of 9 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.80 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 9 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of GBP 33.47B over the last 12 months is up 4.06% from the 12 months before.
| Revenue | GBP 33.47B |
|---|---|
| Revenue Growth (YoY) | +4.06% |
| Gross Profit | GBP 24.42B |
| Operating Income | GBP 6.83B |
| Pretax Income | GBP 5.37B |
| Net Income | GBP 4.34B |
| EBITDA | GBP 8.73B |
| EBIT | GBP 6.52B |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 26.16% of the GBP 72.18B in total assets.
| Working Capital | GBP -2.84B |
|---|---|
| Shareholder Equity | GBP 18.88B |
| Tangible Book Value | GBP -14.73B |
| Total Assets | GBP 72.18B |
| Total Liabilities | GBP 53.69B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After GBP 1.70B of capital spending, operating cash flow left GBP 6.79B of free cash flow.
| Operating Cash Flow | GBP 8.50B |
|---|---|
| Capital Expenditures | GBP 1.70B |
| Free Cash Flow | GBP 6.79B |
| Depreciation and Amortization | GBP 2.21B |
| Dividends Paid | GBP 2.68B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 20.40%, against a 5-year average of 19.78%.
| Gross Margin | 72.96% |
|---|---|
| Operating Margin | 20.40% |
| Pretax Margin | 16.04% |
| Net Margin | 12.96% |
| EBITDA Margin | 26.07% |
| EBIT Margin | 19.48% |
| FCF Margin | 20.30% |
| Gross Margin (5Y Average) | 69.94% |
| Operating Margin (5Y Average) | 19.78% |
| Net Margin (5Y Average) | 22.14% |
Growth
Revenue grew 3.66% a year over 3 years.
| Revenue Growth (3Y CAGR) | +3.66% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.05% |
| FCF Growth (3Y CAGR) | +7.51% |
| FCF Growth (5Y CAGR) | +0.61% |
| Operating Income Growth (3Y CAGR) | +7.23% |
Dividends and Yields
GSK pays out 33.31% of earnings as dividends.
| Dividend Per Share (Annual) | $1.81 |
|---|---|
| Dividend Yield | 3.67% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | -4.40% |
| Dividend Growth (5Y CAGR) | -9.01% |
| Payout Ratio | 33.31% |
| FCF Payout Ratio | 39.44% |
| Earnings Yield | 9.71% |
| FCF Yield | 9.02% |
Stock Splits
The last reverse split was on Jul 19, 2022.
| Last Split Date | Jul 19, 2022 |
|---|---|
| Split Type | Reverse split |
Peer Position
Against 9 similar companies, GSK has the 7th highest P/E.
P/E RatioPeer median 19.8x
P/S RatioPeer median 4.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.31%
Dividend YieldPeer median 2.37%
| P/E Ratio | 10.3x vs 19.8x median |
|---|---|
| P/S Ratio | 2.3x vs 4.1x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4.06% vs +5.31% median |
| Dividend Yield | 3.67% vs 2.37% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GSK
What is GSK's market cap?
GSK has a market cap of $101.13B.
What is GSK's P/E ratio?
GSK has a trailing P/E ratio of 10.3x.
How many shares of GSK are outstanding?
GSK has 2.04B shares outstanding. The count is down 0.71% from a year earlier.
Does GSK pay a dividend?
Yes. GSK pays $1.81 a share a year, a dividend yield of 3.67%.
GSK pages: Overview, Dividends, Charting, Financials, Statistics, Valuation, Competitors, Government Contracts